0001493152-23-023238.txt : 20230703 0001493152-23-023238.hdr.sgml : 20230703 20230703092509 ACCESSION NUMBER: 0001493152-23-023238 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20230628 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230703 DATE AS OF CHANGE: 20230703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biofrontera Inc. CENTRAL INDEX KEY: 0001858685 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473765675 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40943 FILM NUMBER: 231063814 BUSINESS ADDRESS: STREET 1: 120 PRESIDENTIAL WAY, STREET 2: SUITE 330 CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: 781-245-1325 MAIL ADDRESS: STREET 1: 120 PRESIDENTIAL WAY, STREET 2: SUITE 330 CITY: WOBURN STATE: MA ZIP: 01801 8-K 1 form8-k.htm
0001858685 false --12-31 0001858685 2023-06-28 2023-06-28 0001858685 BFRI:CommonStockParValue0.001PerShareMember 2023-06-28 2023-06-28 0001858685 BFRI:PreferredStockPurchaseRightsMember 2023-06-28 2023-06-28 0001858685 BFRI:WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember 2023-06-28 2023-06-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 28, 2023

 

Biofrontera Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40943   47-3765675

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

120 Presidential Way, Suite 330

Woburn, Massachusetts

   01801
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (781) 245-1325

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common stock, par value $0.001 per share   BFRI   The Nasdaq Stock Market LLC
Preferred Stock Purchase Rights       The Nasdaq Stock Market LLC
Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share   BFRIW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the “Exchange Act”) (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 3.03. Material Modification to Rights of Security Holders.

 

On June 28, 2023, Biofrontera Inc., (“the Company”), filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to (i) effect a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s shares of common stock, $0.001 par value (the “Common Stock”), and (ii) effect a related proportional reduction in the number of the Company’s authorized shares of Common Stock from 300,000,000 to 15,000,000 (the “Authorized Share Reduction”).

 

As previously disclosed, at a special meeting held on May 22, 20223, the Company’s stockholders approved the Reverse Stock Split with a ratio within a range of between 1-for-5 and 1-for-25, with the exact ratio to be set at the discretion of the Company’s Board of Directors, and the Authorized Share Reduction, each of which the Board also approved. On June 26, 2023, the Board of Directors approved a ratio of 1-for-20 for the Reverse Stock Split.

 

Pursuant to the Amendment, the Reverse Stock Split and Authorized Share Reduction will be effective at 11:59 p.m. on July 3, 2023 (the “Split Effective Time”), and the Common Stock will be begin trading on the Nasdaq Capital Market on a post-split basis when the market opens on July 5, 2023. The Company’s post-split Common Stock has a new CUSIP number, 09077D 209, but the par value and other terms of the Common Stock were not affected. The trading symbol of the Company’s Common Stock will continue to be “BFRI.”

 

Following the Split Effective Time, every 20 shares of Biofrontera Inc. common stock issued and outstanding will be automatically combined and reclassified into one share of common stock. Outstanding equity-based awards, warrants and other equity rights will be proportionately adjusted pursuant to their terms and the number of shares authorized and reserved for issuance upon vesting of restricted stock units or exercise of stock options and warrants will be reduced proportionately. No fractional shares will be issued as a result of the reverse stock split. Stockholders who would otherwise hold a fractional share as a result of the Reverse Stock Split will receive an additional share of common stock.

 

The Company’s publicly traded warrants will continue to be traded on the Nasdaq Capital Market under the symbol “BFRIW” and the CUSIP number for the warrants will remain unchanged. However, under the terms of the applicable warrant agreement, the number of shares of Common Stock issuable on exercise of each warrant will be proportionately decreased. Specifically, following effectiveness of the Reverse Stock Split, every 20 shares of Common Stock that may be purchased pursuant to the exercise of public warrants now represents one share of Common Stock that may be purchased pursuant to such warrants. Accordingly, for the Company’s warrants trading under the symbol “BFRIW”, every 20 warrants will be exercisable for one share of Common Stock at an exercise price of $100.00 per share of Common Stock. 

 

The Reverse Stock Split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity (other than as a result of the rounding up of fractional shares). Shortly following the Split Effective Time, stockholders of record will be receiving information from Computershare Trust Company, N.A., the Company’s transfer agent, regarding their stock ownership following the Reverse Stock Split. Stockholders who hold their shares in brokerage accounts or in “street name” are not required to take any action in connection with the Reverse Stock Split. Their accounts will be automatically adjusted to reflect the number of shares owned.

 

The foregoing description of the Amendment and the Reverse Stock Split set forth above does not purport to be complete and is qualified in its entirety by reference to the Amendment. A copy of the Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

 

 

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

The disclosures set forth in Item 3.03 of this Current Report on Form 8-K are incorporated into this Item 5.03 by reference.

 

Item 7.01 Regulation FD Disclosure.

 

On July 3, 2023, the Company issued a press release announcing the Reverse Stock Split ratio, a copy of which is attached here as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in Item 7.01 of this Current Report is being furnished and shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

 

Item 9.01 Financial Statements and Exhibits.

 

3.1 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Biofrontera Inc.
99.1 Press Release dated July 3, 2023
104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

July 3, 2023

(Date)

Biofrontera Inc.

(Registrant)

   
 

/s/ E. Fred Leffler III

  E. Fred Leffler III
  Chief Financial Officer

 

 

 EX-3.1 2 ex3-1.htm

 

Exhibit 3.1

 

CERTIFICATE OF AMENDMENT

TO THE

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF

OF

BIOFRONTERA INC.

 

Biofrontera Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify:

 

FIRST. The Amended and Restated Certificate of Incorporation of the Corporation is hereby amended, such amendment to become effective at the Split Effective Time (as defined below), by changing the Article FOURTH, so that, as amended, the first paragraph of said Article FOURTH shall be amended and restated as follows:

 

The total number of shares of capital stock that the Corporation has the authority to issue shall be (i) 15,000,000 shares of common stock, par value $0.001 per share (“Common Stock”) and (ii) 20,000,000 shares of preferred stock, par value $0.001 per share (“Preferred Stock”).

 

SECOND. At 11:59 p.m. on July 3, 2023 (the “Split Effective Time”), every twenty (20) issued and outstanding shares of the Corporation’s common stock, par value $.001 per share, as of the date and time immediately preceding the Split Effective Time (the “Old Shares”), shall automatically be reclassified as and converted into one (1) validly issued, fully paid and non-assessable share of common stock of the Corporation (the “New Shares”) without any further action by the Corporation or the holder thereof, subject to the treatment of fractional share interests as described below (the “Reverse Stock Split”). Further, every right, option and warrant to acquire Old Shares outstanding immediately prior to the Split Effective Time shall, as of the Split Effective Time and without any further action, automatically be reclassified into the right to acquire one (1) New Share for every twenty (20) Old Shares, but otherwise upon the terms of such right, option or warrant (except that the exercise or purchase price of such right, option or warrant shall be proportionately adjusted). No fractional shares shall be issued in connection with the Reverse Stock Split. Stockholders who otherwise would be entitled to receive fractional shares of common stock shall receive that number of New Shares based on the conversion ratio of their shares of Old Shares to New Shares set forth above, rounded up to the next whole share of common stock.

 

THIRD. That a resolution was duly adopted by unanimous written consent of the directors of the Corporation, pursuant to Section 242 of the DGCL, setting forth the above mentioned amendment to the Amended and Restated Certificate of Incorporation and declaring said amendment to be advisable.

 

FOURTH. That this amendment was duly authorized by the holders of a majority of the voting stock of the Corporation entitled to vote at a duly authorized meeting of the stockholders of the Corporation held on May 22, 2023. Said amendment was duly adopted in accordance with the provisions of the DGCL.

 

IN WITNESS WHEREOF, this Certificate of Amendment of the Amended and Restated Certificate of Incorporation has been signed by the Chief Financial Officer of the Corporation this 28th day of June, 2023.

 

  BIOFRONTERA INC.
     
  By: /s/ E. Fred Leffler III
  Name: E. Fred Leffler, III
  Title: Chief Financial Officer

 

 
 EX-99.1 3 ex99-1.htm

 

Exhibit 99.1

 

Biofrontera Inc. Announces 1-for-20 Reverse Stock Split

 

WOBURN, Mass. (July 3, 2023) – Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 that will become effective after the close of trading at 11:59 p.m. today. Biofrontera Inc. common stock will begin trading on Nasdaq on a split-adjusted basis when the market opens on Wednesday, July 5, 2023 under the existing symbol, BFRI, and under a new CUSIP number, 09077D 209.

 

Upon effectiveness of the reverse stock split, every 20 shares of Biofrontera Inc. common stock issued and outstanding will be automatically combined into one share of common stock. Outstanding equity-based awards and other equity rights will be proportionately adjusted. No fractional shares will be issued as a result of the reverse stock split. Stockholders otherwise entitled to receive a fractional share as a result of the reverse stock split will automatically receive an additional fraction of a share of common stock to round up to the next whole share.

 

The Company’s publicly traded warrants will continue to be traded on Nasdaq under the symbol “BFRIW” and the CUSIP number for the warrants will remain unchanged. However, under the terms of the applicable warrant agreement, the number of shares of common stock issuable on exercise of each warrant will be proportionately decreased. Specifically, on a split-adjusted basis, every 20 shares of common stock that may be purchased pursuant to the exercise of public warrants now represents one share of common stock that may be purchased pursuant to such warrants. Accordingly, for the Company’s warrants trading under the symbol “BFRIW”, every 20 warrants will be exercisable for one share of common stock at an exercise price of $100.00 per share.

 

This reverse stock split is primarily intended to bring the Company into compliance with Nasdaq’s minimum bid price requirement for continued listing.

 

“This reverse stock split, which was approved by our shareholders and authorized by our Board of Directors, should allow Biofrontera to regain compliance with Nasdaq’s continued-listing requirements. Additionally, we believe the post-split stock price may make an investment in Biofrontera more attractive to a broader group of investors,” commented Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera Inc.

 

The reverse stock split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity (other than as a result of the rounding up of fractional shares). Stockholders of record will be receiving information from Computershare Trust Company, N.A., the Company’s transfer agent, regarding their stock ownership following the reverse stock split. Stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the reverse stock split, subject to such broker’s particular processes, and will not be required to take any action in connection with the reverse stock split.

 

Additional information concerning the reverse stock split can be found in Biofrontera Inc.’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 21, 2023.

 

About Biofrontera Inc.

 

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of products for the treatment of dermatologic conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter.

 

 
 

 

Forward-Looking Statements

 

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to for the implementation of the reverse stock split, the impact of the reverse stock split on the Company and its stock price, the likelihood of regaining compliance with Nasdaq’s listing requirements and the investment appeal of the Company. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of any extraordinary external events; any changes in the Company’s relationship with its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED® in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz® in combination with BF-RhodoLED® is consistent with the Company’s expectations; the Company’s ability to comply with public company requirements; the Company’s ability to regain compliance with Nasdaq continued listing standards, the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed in the Company’s filings with the SEC, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

 

Contact:

 

LHA Investor Relations

Tirth T. Patel

212-201-6614

tpatel@lhai.com

 

# # #

 

 

 

 

 GRAPHIC 4 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 5 bfri-20230628.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 6 bfri-20230628_def.xml XBRL DEFINITION FILE EX-101.LAB 7 bfri-20230628_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common stock, par value $0.001 per share Preferred Stock Purchase Rights Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 8 bfri-20230628_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Jun. 28, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 28, 2023
Current Fiscal Year End Date --12-31
Entity File Number 001-40943
Entity Registrant Name Biofrontera Inc.
Entity Central Index Key 0001858685
Entity Tax Identification Number 47-3765675
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 120 Presidential Way
Entity Address, Address Line Two Suite 330
Entity Address, City or Town Woburn
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01801
City Area Code (781)
Local Phone Number 245-1325
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Entity Information, Former Legal or Registered Name Not Applicable
Common stock, par value $0.001 per share  
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol BFRI
Security Exchange Name NASDAQ
Preferred Stock Purchase Rights  
Title of 12(b) Security Preferred Stock Purchase Rights
Security Exchange Name NASDAQ
Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share  
Title of 12(b) Security Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share
Trading Symbol BFRIW
Security Exchange Name NASDAQ
XML 10 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001858685 2023-06-28 2023-06-28 0001858685 BFRI:CommonStockParValue0.001PerShareMember 2023-06-28 2023-06-28 0001858685 BFRI:PreferredStockPurchaseRightsMember 2023-06-28 2023-06-28 0001858685 BFRI:WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember 2023-06-28 2023-06-28 iso4217:USD shares iso4217:USD shares 0001858685 false --12-31 8-K 2023-06-28 Biofrontera Inc. DE 001-40943 47-3765675 120 Presidential Way Suite 330 Woburn MA 01801 (781) 245-1325 Not Applicable false false false false Common stock, par value $0.001 per share BFRI NASDAQ Preferred Stock Purchase Rights NASDAQ Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share BFRIW NASDAQ true false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 4 26 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://biofrontera.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-60546-SecurityExchangeName-TradingSymbol, NoTradingSymbolFlag-Dependency] In submission type 8-K, SecurityExchangeName should have a value if one of TradingSymbol, NoTradingSymbolFlag has a value in context From2023-06-282023-06-28_custom_PreferredStockPurchaseRightsMember. form8-k.htm 263 form8-k.htm bfri-20230628.xsd bfri-20230628_def.xml bfri-20230628_lab.xml bfri-20230628_pre.xml ex3-1.htm ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 31 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "bfri-20230628_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "bfri-20230628_lab.xml" ] }, "presentationLink": { "local": [ "bfri-20230628_pre.xml" ] }, "schema": { "local": [ "bfri-20230628.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 67, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 26, "memberCustom": 3, "memberStandard": 0, "nsprefix": "BFRI", "nsuri": "http://biofrontera.com/20230628", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-06-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://biofrontera.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-06-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "BFRI_CommonStockParValue0.001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock, par value $0.001 per share" } } }, "localname": "CommonStockParValue0.001PerShareMember", "nsuri": "http://biofrontera.com/20230628", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "domainItemType" }, "BFRI_PreferredStockPurchaseRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Purchase Rights" } } }, "localname": "PreferredStockPurchaseRightsMember", "nsuri": "http://biofrontera.com/20230628", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "domainItemType" }, "BFRI_WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share" } } }, "localname": "WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember", "nsuri": "http://biofrontera.com/20230628", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 18 0001493152-23-023238-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-023238-xbrl.zip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�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end